CRISPR/Cas9 gene editor Editas Medicine (NASDAQ:EDIT) and modified CRISPR gene editor Beam Therapeutics (NASDAQ:BEAM) are up 21% and 35%, respectively, premarket on chatter that a deal is imminent.


Other CRISPR stocks to watch: CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics (NASDAQ:NTLA)

Update: Both companies have declined to comment on the speculation.

Enterprise value of EDIT and BEAM

Source link